Effect of the Sera of Patients with Multiple Sclerosis on Apoptosis and Nitric Oxide Production of Endothelial Cells (original) (raw)

Interferon-beta-1b protects against multiple sclerosis-induced endothelial cells apoptosis

Frontiers in Bioscience, 2012

2008

Lymphocyte subpopulations, oxidative burst and apoptosis in peripheral blood cells of patients with multiple sclerosis-effect of interferon-beta

Ulf Strauss

Autoimmunity, 2003

View PDFchevron_right

IFNβ therapy progressively normalizes the increased ex vivo T lymphocyte apoptosis observed in active patients with multiple sclerosis

Melchor Alvarez-mon

Clinical Immunology, 2009

View PDFchevron_right

The Effect of IFN-β 1a on Biochemical Factors in Multiple Sclerosis Patients

Hossein Ali Ebrahimi Meimand

View PDFchevron_right

Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy

Jeanie McGee

Neurological Research, 2012

View PDFchevron_right

Multiple sclerosis as a vascular disease

alireza minagar

Neurological Research, 2006

View PDFchevron_right

Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment

Mathilde Kouwenhoven

Clinical and Experimental Immunology, 2000

View PDFchevron_right

IFN-β and multiple sclerosis: From etiology to therapy and back

Silvia Romano

Cytokine & Growth Factor Reviews, 2014

View PDFchevron_right

We should focus more on finding therapeutic targets for the non-inflammatory damage in MS – No

Robert Weissert

Multiple Sclerosis Journal, 2018

View PDFchevron_right

Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis

Elaine Oliveira

2009

View PDFchevron_right

Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis

Mohsen Khademi

Journal of Neuroimmunology, 2000

View PDFchevron_right

Vascular function and multiple sclerosis

Melissa Witman

Journal of Neurology, 2011

View PDFchevron_right

Diverse Targets for Intervention during Inflammatory and Neurodegenerative Phases of Multiple Sclerosis

Lawrence Steinman, Scott Zamvil

Neuron, 2003

View PDFchevron_right

Editorial of Special Issue “Multiple Sclerosis: Diagnosis and Treatment II”

Victor Rivera

Biomedicines

View PDFchevron_right

Mechanisms of tissue injury in multiple sclerosis: opportunities for neuroprotective therapy

Dr. Uma Ladiwala

Advances in Research on Neurodegeneration, 2000

View PDFchevron_right

EXPRESSION OF TNF-α mRNA BY PERIPHERAL BLOOD MONONUCLEAR CELLS OF MULTIPLE SCLEROSIS PATIENTS TREATED WITH IFN-β 1A

Paola Sarchielli

Cytokine, 2001

View PDFchevron_right

Editorial: Multiple Sclerosis: Pathogenesis and Therapeutics

Vasso Apostolopoulos

Medicinal Chemistry, 2018

View PDFchevron_right

Multiple Sclerosis: New Pathophysiological and Therapeutic Concepts

Clive Hawkins

2001

View PDFchevron_right

The molecular study of IFNβ pleiotropic roles in MS treatment

Maryam Kay

Iranian journal of neurology, 2013

View PDFchevron_right

Pathogenesis and treatment of multiple sclerosis (MS)

Archana NAvale

The Internet Journal of Neurology, 2009

View PDFchevron_right

Bio-markers of disease activity and response to therapy in multiple sclerosis

Michal Abraham

Clinical Neurology and Neurosurgery, 2004

View PDFchevron_right

Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS

Michael Dwyer

Neurology(R) neuroimmunology & neuroinflammation, 2015

View PDFchevron_right

Multiple sclerosis and cerebral endothelial dysfunction: Mechanisms

Ganta Chaitanya

Pathophysiology, 2011

View PDFchevron_right

Determination of cytokine levels in multiple sclerosis patients and their relevance with patients' response to Cinnovex

Arezou Sayad

Cytokine, 2017

View PDFchevron_right

Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-α)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-β) treatment

Volkan Ozenci

Clinical and Experimental Immunology, 2000

View PDFchevron_right

Effects of interferon and glatiramer acetate on cytokine patterns in multiple sclerosis patients

Ghasem Mosayebi

Cytokine, 2020

View PDFchevron_right

Interferon Beta in Multiple Sclerosis

tapani keranen

Bmj, 1997

View PDFchevron_right

The Immunogenicity of Disease-Modifying Therapies for Multiple Sclerosis: Clinical Implications for Neurologists

Scott Zamvil

The Neurologist, 2007

View PDFchevron_right

Nitric oxide synthase expression and enzymatic activity in multiple sclerosis

Jette Frederiksen

Acta Neurologica Scandinavica, 2004

View PDFchevron_right

Editorial: Multiple Sclerosis – From Bench to Bedside: Currents Insights Into Pathophysiological Concepts and Their Potential Impact on Patients

Paulus Rommer

Frontiers in Immunology

View PDFchevron_right

Nitric oxide as an activity marker in multiple sclerosis

Fethi Idiman

Journal of Neurology, 2003

View PDFchevron_right

A basic overview of multiple sclerosis immunopathology

N. Grigoriadis

European Journal of Neurology, 2015

View PDFchevron_right

The Effects of IFN-β 1a on the Expression of Inflammasomes and Apoptosis-Associated Speck-Like Proteins in Multiple Sclerosis Patients

Hossein Ali Ebrahimi Meimand

Molecular Neurobiology, 2016

View PDFchevron_right

Effect of the Sera of Patients with Multiple Sclerosis on Apoptosis and Nitric Oxide Production of Endothelial Cells (original) (raw)

Related papers